Regulation - Regulation, aclidinium


Current filters:


Popular Filters

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol


US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall


Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Forest Labs and Almirall opt to delay US filing for combo COPD drug


USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG


The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

Almirall's aclidinium approved in Europe for COPD maintenance treatment


Spain's leading drugmaker, Almirall (ALM: MC) says that the European Commission has granted marketing…

aclidiniumAlmirallBretaris GenuairEklira GenuairEuropeMenariniPharmaceuticalRegulationRespiratory and Pulmonary

US FDA delays approval of Almirall and Forest Laboratories' COPD drug


The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Back to top